Treatment of myelodysplastic syndromes with hemopoietic growth factors.
Greenberg
P L
PL
Division of Hematology, Stanford University School of Medicine, CA 94305.
D004921:Erythropoietin / Q000627:therapeutic use*; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use*; D016298:Hematopoietic Cell Growth Factors / Q000627:therapeutic use; D006801:Humans; D007377:Interleukin-3 / Q000627:therapeutic use*; D009190:Myelodysplastic Syndromes / Q000628:therapy*
D016298:Hematopoietic Cell Growth Factors; D007377:Interleukin-3; D004921:Erythropoietin; D016179:Granulocyte Colony-Stimulating Factor; D016178:Granulocyte-Macrophage Colony-Stimulating Factor